$7.65 +0.61 (8.67%) Arrowhead Pharmaceuticals Inc - NASDAQ

Sep. 29, 2016 | 12:09 PM
Last Trade: 7.65
Trade Time: Sep 29 12:09 PM Eastern Daylight Time
Change: +0.61 (8.67%)
Prev Close: 7.04
Open: 8.05
Bid: 7.64
Ask: 7.65
  1. No results found.
  1. Mid-Day Market Update: Breitburn Energy Partners Drops Following News of Distribution Suspension; Mattress Firm Shares Surge

    Benzinga | Dec. 1, 2015 | 12:03PM EST
  2. Arrowhead Late-Breaking Clinical Data Shows that ARC-520 Can Produce Deep and Durable Reductions of Hepatitis B Viral Antigens and DNA

    Benzinga | Nov. 16, 2015 | 11:02AM EST
  3. US Stock Futures Edge Higher Ahead Of Empire State Manufacturing Index

    Benzinga | Nov. 16, 2015 | 07:07AM EST
  4. Arrowhead Presents Positive Data on ARC-520 in Hepatitis B Infected Chimpanzees at AASLD Liver Meeting 2015

    Benzinga | Nov. 15, 2015 | 18:43PM EST
  5. Benzinga's Top #PreMarket Gainers

    Benzinga | Oct. 13, 2015 | 08:17AM EST
  6. 10 Stocks Moving In Monday's After-Hours Session

    Benzinga | Sep. 28, 2015 | 16:47PM EST
  7. Arrowhead's good test result

    IBD | Sep. 24, 2015 | 18:35PM EST
  8. Arrowhead Hits Target In Hepatitis B Drug Trial

    IBD | Sep. 24, 2015 | 10:51AM EST
  9. Mid-Morning Market Update: Markets Tumble; Accenture Tops Q4 Estimates

    Benzinga | Sep. 24, 2015 | 10:33AM EST
  10. Morning Market Gainers

    Benzinga | Sep. 24, 2015 | 09:41AM EST
  11. Benzinga's Top #PreMarket Gainers

    Benzinga | Sep. 24, 2015 | 08:08AM EST
  12. Morning Market Gainers

    Benzinga | Sep. 11, 2015 | 09:48AM EST
  13. Arrowhead Initiates Dosing of ARC-AAT in Patients with Alpha-1 Antitrypsin Deficiency

    Benzinga | Jul. 2, 2015 | 07:33AM EST
  14. Can Hepatitis B Be A Blockbuster Bug?

    IBD | Jul. 1, 2015 | 08:02AM EST
  15. Arrowhead Receives Regulatory Clearance to Begin Additional Phase 2b Studies of Hepatitis B Candidate ARC-520

    Benzinga | Jun. 17, 2015 | 07:30AM EST
Trading Center